Richard Young is a co-founder of Paratus Sciences, as well as a Professor of Biology at MIT and a Member of the Whitehead Institute, where his work focuses on gene regulation in health and disease. He is recognized for developing genome analysis technologies and using them to identify transcriptional regulatory mechanisms that become dysregulated in disease. His laboratory studies transcriptional and epigenetic regulation of gene expression in mammalian cells, with emphasis on gene control in early development and in cancer.
Richard joined MIT and the Whitehead Institute after completing a Ph.D. at Yale University, and postdoctoral research at Stanford University. He has served as an advisor to the National Institutes of Health and the World Health Organization, and Scientific American recognized him in 2006 as one of the top 50 leaders in science, technology and business. He is a member of the National Academy of Sciences and the National Academy of Medicine.
He has been a founder and board member of additional biotech companies, including Computational Biology Corporation (acquired by Agilent Technologies), CAMP4 Therapeutics (NASDAQ: CAMP), Dewpoint Therapeutics and Syros Pharmaceuticals (NASDAQ: SYRS).
Richard holds a Ph.D. from Yale University and a B.S. from Indiana University.
